Advances in direct T-cell alloreactivity: Function, avidity, biophysics and structure

American Journal of Transplantation

Volumn 12, Issue 1, 2012, Pages 15-26

  Smith, C ^a   Miles, J J ^a,b   Khanna, R ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

alloreactive T cells; Alloreactivity; allorecognition; bone marrow; HLA antigens; memory T cells; transplant; transplant immunobiology; viral immunity; viral infection

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ADAPTIVE IMMUNITY; ALLELE; ALLOIMMUNITY; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL POPULATION; CELL STRUCTURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ADAPTATION, PHYSIOLOGICAL; ANTIBODY AFFINITY; BIOPHYSICS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MOLECULAR MIMICRY; T-LYMPHOCYTES;

EID: 84855961969     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03863.x     Document Type: Review

References (128)

1. Doherty PC, Hou S, Tripp RA,. CD8+ T-cell memory to viruses. Curr Opin Immunol 1994; 6: 545-552.
2. Janeway CA Jr,. Thymic selection: Two pathways to life and two to death. Immunity 1994; 1: 3-6. (Pubitemid 124000690)
3. Nikolic-Zugic J, Bevan MJ,. Role of self-peptides in positively selecting the T-cell repertoire. Nature 1990; 344: 65-67.
4. Vyas JM, Van der Veen AG, Ploegh HL,. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008; 8: 607-618.
5. Rivino L, Messi M, Jarrossay D, Lanzavecchia A, Sallusto F, Geginat J,. Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med 2004; 200: 725-735. (Pubitemid 39299459)
6. Appay V, Dunbar PR, Callan M, et al,. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: 379-385. (Pubitemid 34407033)
7. Sallusto F, Geginat J, Lanzavecchia A,. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763. (Pubitemid 38680440)
8. Geginat J, Sallusto F, Lanzavecchia A,. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001; 194: 1711-1719. (Pubitemid 34028651)
9. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR,. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
10. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR,. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186: 65-70. (Pubitemid 27304848)
11. Smith CM, Wilson NS, Waithman J, et al,. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5: 1143-1148. (Pubitemid 39549628)
12. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A,. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
13. Wolint P, Betts MR, Koup RA, Oxenius A,. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med 2004; 199: 925-936. (Pubitemid 38481084)
14. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE,. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991; 173: 747-750.
15. Reinhardt RL, Liang HE, Locksley RM,. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009; 10: 385-393.
16. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B,. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192: 1553-1562.
17. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL,. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357. (Pubitemid 16136806)
18. Zhu J, Yamane H, Paul WE,. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010; 28: 445-489.
19. Rudolph MG, Stanfield RL, Wilson IA,. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 241: 419-466.
20. Stone JD, Chervin AS, Kranz DM,. T-cell receptor binding affinities and kinetics: Impact on T-cell activity and specificity. Immunology 2009; 126: 165-176.
21. Ely LK, Green KJ, Beddoe T, et al,. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection. J Immunol 2005; 174: 5593-5601. (Pubitemid 40593200)
22. Rosette C, Werlen G, Daniels MA, et al,. The impact of duration versus extent of TCR occupancy on T cell activation: A revision of the kinetic proofreading model. Immunity 2001; 15: 59-70. (Pubitemid 32728320)
23. Garcia KC, Tallquist MD, Pease LR, et al,. Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: Affinity measurements and crystallization. Proc Natl Acad Sci USA 1997; 94: 13838-13843. (Pubitemid 28009671)
24. Slansky JE, Rattis FM, Boyd LF, et al,. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13: 529-538.
25. Lyons DS, Lieberman SA, Hampl J, et al,. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996; 5: 53-61. (Pubitemid 26254784)
26. Tian S, Maile R, Collins EJ, Frelinger JA,. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol 2007; 179: 2952-2960.
27. Smith-Garvin JE, Koretzky GA, Jordan MS,. T cell activation. Annu Rev Immunol 2009; 27: 591-619.
28. Krummel MF, Sjaastad MD, Wulfing C, Davis MM,. Differential clustering of CD4 and CD3zeta during T cell recognition. Science 2000; 289: 1349-1352. (Pubitemid 30656051)
29. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM,. Direct observation of ligand recognition by T cells. Nature 2002; 419: 845-849. (Pubitemid 35238571)
30. Krogsgaard M, Li QJ, Sumen C, Huppa JB, Huse M, Davis MM,. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature 2005; 434: 238-243. (Pubitemid 40388057)
31. Wulfing C, Sumen C, Sjaastad MD, Wu LC, Dustin ML, Davis MM,. Costimulation and endogenous MHC ligands contribute to T cell recognition. Nat Immunol 2002; 3: 42-47. (Pubitemid 34065616)
32. Holler PD, Kranz DM,. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18: 255-264. (Pubitemid 36263000)
33. Kerry SE, Buslepp J, Cramer LA, et al,. Interplay between TCR affinity and necessity of coreceptor ligation: High-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol 2003; 171: 4493-4503. (Pubitemid 37310564)
34. Wooldridge L, van den Berg HA, Glick M, et al,. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 2005; 280: 27491-27501. (Pubitemid 41076859)
35. Wooldridge L, Laugel B, Ekeruche J, et al,. CD8 controls T cell cross-reactivity. J Immunol 2010; 185: 4625-4632.
36. Rist M, Smith C, Bell MJ, Burrows SR, Khanna R,. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: A new paradigm for self-/nonself-recognition. Blood 2009; 114: 2244-2253.
37. Sharpe AH,. Mechanisms of costimulation. Immunol Rev 2009; 229: 5-11.
38. Sharpe AH, Freeman GJ,. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126. (Pubitemid 37323235)
39. Ghosh P, Tan TH, Rice NR, Sica A, Young HA,. The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc Natl Acad Sci U S A 1993; 90: 1696-1700. (Pubitemid 23069923)
40. Shahinian A, Pfeffer K, Lee KP, et al,. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261: 609-612. (Pubitemid 23278372)
41. Suresh M, Whitmire JK, Harrington LE, et al,. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001; 167: 5565-5573. (Pubitemid 33062745)
42. Viola A, Lanzavecchia A,. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-106. (Pubitemid 26255435)
43. Borowski AB, Boesteanu AC, Mueller YM, et al,. Memory CD8+ T cells require CD28 costimulation. J Immunol 2007; 179: 6494-6503.
44. Fuse S, Zhang W, Usherwood EJ,. Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol 2008; 180: 1148-1157.
45. Weekes MP, Carmichael AJ, Wills MR, Mynard K, Sissons JG,. Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol 1999; 162: 7569-7577. (Pubitemid 29277739)
46. Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH, Watts TH,. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol 2004; 172: 981-988. (Pubitemid 38113757)
47. Kim YJ, Brutkiewicz RR, Broxmeyer HE,. Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells. Blood 2002; 100: 3253-3260. (Pubitemid 35217075)
48. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH,. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004; 101: 1291-1296. (Pubitemid 38182682)
49. Slifka MK, Whitton JL,. Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers. J Immunol 2000; 164: 208-216. (Pubitemid 30012992)
50. London CA, Lodge MP, Abbas AK,. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 2000; 164: 265-272. (Pubitemid 30012999)
51. Masopust D, Vezys V, Marzo AL, Lefrancois L,. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 2413-2417. (Pubitemid 32231804)
52. Croft M, Bradley LM, Swain SL,. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994; 152: 2675-2685.
53. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR,. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008; 319: 198-202.
54. Zammit DJ, Cauley LS, Pham QM, Lefrancois L,. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005; 22: 561-570. (Pubitemid 40719192)
55. Kimachi K, Croft M, Grey HM,. The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur J Immunol 1997; 27: 3310-3317. (Pubitemid 28018028)
56. Rogers PR, Dubey C, Swain SL,. Qualitative changes accompany memory T cell generation: Faster, more effective responses at lower doses of antigen. J Immunol 2000; 164: 2338-2346. (Pubitemid 30115460)
57. Farber DL,. Biochemical signaling pathways for memory T cell recall. Semin Immunol 2009; 21: 84-91.
58. Chandok MR, Okoye FI, Ndejembi MP, Farber DL,. A biochemical signature for rapid recall of memory CD4 T cells. J Immunol 2007; 179: 3689-3698.
59. Ndejembi MP, Teijaro JR, Patke DS, et al,. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698-7706. (Pubitemid 44846285)
60. Wang EC, Moss PA, Frodsham P, Lehner PJ, Bell JI, Borysiewicz LK,. CD8highCD57+ T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. J Immunol 1995; 155: 5046-5056. (Pubitemid 3010847)
61. Khan N, Shariff N, Cobbold M, et al,. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169: 1984-1992. (Pubitemid 34857662)
62. Casazza JP, Betts MR, Price DA, et al,. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865-2877. (Pubitemid 46026164)
63. van Leeuwen EM, Gamadia LE, Baars PA, Remmerswaal EB, ten Berge IJ, van Lier RA,. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J Immunol 2002; 169: 5838-5843. (Pubitemid 35291687)
64. Afzali B, Lechler RI, Hernandez-Fuentes MP,. Allorecognition and the alloresponse: Clinical implications. Tissue Antigens 2007; 69: 545-556. (Pubitemid 46733686)
65. Macdonald WA, Chen Z, Gras S, et al,. T cell allorecognition via molecular mimicry. Immunity 2009; 31: 897-908.
66. Yin L, Huseby E, Scott-Browne J, et al,. A single T cell receptor bound to major histocompatibility complex class I and class II glycoproteins reveals switchable TCR conformers. Immunity 2011; 35: 23-33.
67. Colf LA, Bankovich AJ, Hanick NA, et al,. How a single T cell receptor recognizes both self and foreign MHC. Cell 2007; 129: 135-146. (Pubitemid 46507586)
68. Cole DK, Pumphrey NJ, Boulter JM, et al,. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178: 5727-5734. (Pubitemid 46674369)
69. Miles JJ, Douek DC, Price DA,. Bias in the alphabeta T-cell repertoire: Implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011; 89: 375-387.
70. Kjer-Nielsen L, Clements CS, Purcell AW, et al,. A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity 2003; 18: 53-64. (Pubitemid 36120687)
71. Sherman LA, Chattopadhyay S,. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385-402. (Pubitemid 23115013)
72. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA,. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973-981. (Pubitemid 32060253)
73. Maruya E, Takemoto S, Terasaki PI,. HLA matching: identification of permissible HLA mismatches. Clin Transpl 1993: 511-520.
74. Doxiadis, II, Smits JM, Schreuder GM, et al,. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996; 348: 850-853. (Pubitemid 26320900)
75. Coupel S, Giral-Classe M, Karam G, et al,. Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months. Kidney Int 2003; 64: 674-680.
76. Doxiadis, II, de Fijter JW, Mallat MJ, et al,. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83: 1207-1213. (Pubitemid 46743682)
77. Gilks WR, Bradley BA, Gore SM, Klouda PT,. Substantial benefits of tissue matching in renal transplantation. Transplantation 1987; 43: 669-674. (Pubitemid 17075333)
78. Opelz G,. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 1985; 40: 240-243. (Pubitemid 15023179)
79. Kiepiela P, Leslie AJ, Honeyborne I, et al,. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432: 769-775.
80. Mifsud NA, Purcell AW, Chen W, Holdsworth R, Tait BD, McCluskey J,. Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity. Am J Transplant 2008; 8: 121-132.
81. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB,. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002; 195: 893-905. (Pubitemid 34286760)
82. Argaet VP, Schmidt CW, Burrows SR, et al,. Dominant selection of an invariant T-cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med 1994; 180: 2335-2340. (Pubitemid 24351615)
83. Wynn KK, Fulton Z, Cooper L, et al,. Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood 2008; 111: 4283-4292.
84. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argaet VP,. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 1995; 182: 1703-1715.
85. Crompton L, Khan N, Khanna R, Nayak L, Moss PA,. CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 2008; 111: 2053-2061. (Pubitemid 351451517)
86. Wynn KK, Crough T, Campbell S, et al,. Narrowing of T-cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients. Immunol Cell Biol 2010; 88: 125-135.
87. Morice A, Charreau B, Neveu B, et al,. Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules. PLoS One 2011; 5: e12120.
88. Burrows SR, Khanna R, Burrows JM, Moss DJ,. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: Implications for graft-versus-host disease. J Exp Med 1994; 179: 1155-1161. (Pubitemid 24091774)
89. Burrows SR, Silins SL, Khanna R, et al,. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: Degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 1997; 27: 1726-1736. (Pubitemid 27302856)
90. Landais E, Morice A, Long HM, et al,. EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. J Immunol 2006; 177: 1427-1433. (Pubitemid 44092475)
91. Elkington R, Khanna R,. Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: Implications for graft-versus-host disease. Blood 2005; 105: 1362-1364. (Pubitemid 40170915)
92. Amir AL, D'Orsogna LJ, Roelen DL, et al,. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115: 3146-3157.
93. Matzinger P, Bevan MJ,. Hypothesis: Why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977; 29: 1-5. (Pubitemid 8070904)
94. Bevan MJ,. High determinant density may explain the phenomenon of alloreactivity. Immunol Today 1984; 5: 128-130.
95. Felix NJ, Donermeyer DL, Horvath S, et al,. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8: 388-397. (Pubitemid 46745414)
96. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL,. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27-47. (Pubitemid 23173241)
97. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr,. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622-627. (Pubitemid 21912570)
98. Rudensky A, Rath S, Preston-Hurlburt P, Murphy DB, Janeway CA Jr,. On the complexity of self. Nature 1991; 353: 660-662. (Pubitemid 21912583)
99. Murphy DB, Rath S, Pizzo E, et al,. Monoclonal antibody detection of a major self peptide. MHC class II complex. J Immunol 1992; 148: 3483-3491.
100. Logunova NN, Viret C, Pobezinsky LA, et al,. Restricted MHC-peptide repertoire predisposes to autoimmunity. J Exp Med 2005; 202: 73-84. (Pubitemid 41002911)
101. Ciubotariu R, Liu Z, Colovai AI, et al,. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398-405. (Pubitemid 28067337)
102. Xu Q, Lee J, Keller M, Burlingham WJ,. Analysis of indirect pathway CD4+ T cells in a patient with metastable tolerance to a kidney allograft: Possible relevance to superior graft survival of HLA class II closely matched renal allografts. Transpl Immunol 2009; 20: 203-208.
103. Slachta CA, Jeevanandam V, Goldman B, Lin WL, Platsoucas CD,. Coronary arteries from human cardiac allografts with chronic rejection contain oligoclonal T cells: Persistence of identical clonally expanded TCR transcripts from the early post-transplantation period (endomyocardial biopsies) to chronic rejection (coronary arteries). J Immunol 2000; 165: 3469-3483.
104. Doumaid K, van Miert PP, Vaessen LM, Remmerswaal EB, Weimar W, Boog CJ,. Modulation of the T cell receptor beta chain repertoire after heart transplantation. Transpl Immunol 2000; 8: 83-94.
105. Douillard P, Josien R, Pannetier C, Bonneville M, Soulillou JP, Cuturi MC,. Selection of T cell clones with restricted TCR-CDR3 lengths during in vitro and in vivo alloresponses. Int Immunol 1998; 10: 71-83. (Pubitemid 28048357)
106. Baron C, Sachs DH, LeGuern C,. A particular TCR beta variable region used by T cells infiltrating kidney transplants. J Immunol 2001; 166: 2589-2596. (Pubitemid 32173496)
107. Vignes C, Chiffoleau E, Brouard S, et al,. Anti-TCR Vbeta-specific DNA vaccination prolongs heart allograft survival in adult rats. Eur J Immunol 2000; 30: 2460-2464.
108. Melchior B, Nerriere-Daguin V, Degauque N, et al,. Compartmentalization of TCR repertoire alteration during rejection of an intrabrain xenograft. Exp Neurol 2005; 192: 373-383. (Pubitemid 40341682)
109. Gagne K, Brouard S, Giral M, et al,. Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 2000; 164: 1553-1563. (Pubitemid 30067273)
110. Brouard S, Dupont A, Giral M, et al,. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5: 330-340. (Pubitemid 40179520)
111. Miqueu P, Degauque N, Guillet M, et al,. Analysis of the peripheral T-cell repertoire in kidney transplant patients. Eur J Immunol 2010; 40: 3280-3290.
112. Matsutani T, Ohashi Y, Yoshioka T, et al,. Skew in T-cell receptor usage and clonal T-cell expansion in patients with chronic rejection of transplanted kidneys. Transplantation 2003; 75: 398-407. (Pubitemid 36222969)
113. Duquesnoy RJ,. Clinical usefulness of HLA matchmaker in HLA epitope matching for organ transplantation. Curr Opin Immunol 2008; 20: 594-601.
114. Macedo C, Orkis EA, Popescu I, et al,. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009; 9: 2057-2066.
115. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL,. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008; 8: 1652-1661.
116. Akbar AN, Amlot PL, Timms A, Lombardi G, Lechler R, Janossy G,. The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantation. Clin Exp Immunol 1990; 81: 225-231. (Pubitemid 20242526)
117. Hruban RH, Beschorner WE, Baumgartner WA, et al,. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 1990; 137: 871-882. (Pubitemid 20337802)
118. Ibrahim S, Dawson DV, Sanfilippo F,. Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation 1995; 59: 724-728.
119. Sheil JM, Bevan MJ, Lefrancois L,. Characterization of dual-reactive H-2Kb-restricted anti-vesicular stomatitus virus and alloreactive cytotoxic T cells. J Immunol 1987; 138: 3654-3660. (Pubitemid 17078229)
120. Yang H, Welsh RM,. Induction of alloreactive cytotoxic T cells by acute virus infection of mice. J Immunol 1986; 136: 1186-1193. (Pubitemid 16156214)
121. Adams AB, Williams MA, Jones TR, et al,. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895. (Pubitemid 38057733)
122. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
123. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781. (Pubitemid 41215486)
124. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE,. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566. (Pubitemid 19155945)
125. Razonable RR, Rivero A, Rodriguez A, et al,. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464. (Pubitemid 33108862)
126. von Willebrand E, Pettersson E, Ahonen J, Hayry P,. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986; 42: 364-367. (Pubitemid 16005761)
127. Mifsud NA, Nguyen TH, Tait BD, Kotsimbos TC,. Quantitative and functional diversity of cross-reactive EBV-specific CD8+ T cells in a longitudinal study cohort of lung transplant recipients. Transplantation 2010; 90: 1439-1449.
128. D'Orsogna LJ, Roelen DL, van der Meer-Prins EM, et al,. Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells. Transplantation 2011; 91: 494-500.